3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Peripheral Nervous System Diseases
1
Breast Neoplasms
1
Interventions
Cyclophosphamide
13
Methotrexate
12
Cytarabine
11
Dexamethasone
10
Vincristine
9
Etoposide
7
Radiotherapy
6
Mercaptopurine
6
Daunorubicin
6
Asparaginase
6
pegaspargase
5
blinatumomab
5
Dasatinib
5
Prednisone
4
Methylprednisolone
4
Filgrastim
4
Doxorubicin
4
ruxolitinib
3
N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide
3
Idarubicin
3
Granulocyte Colony-Stimulating Factor
3
Drug Therapy
3
Busulfan
3
Antilymphocyte Serum
3
venetoclax
2
fludarabine phosphate
2
fludarabine
2
etoposide phosphate
2
calaspargase pegol
2
Thiotepa
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2/3
×
Precursor Cell Lymphoblastic Leukemia-Lymphoma
×
Pentoxifylline
×
Clear all
NCT02451774
2018-05-09
PTX-II
University of Guadalajara
Phase 2/3
Unknown
44 enrolled